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Background: Epidemiologic studies have reported various results relating phytoestrogens to prostate cancer (PCa).
The aim of this study was to provide a comprehensive meta-analysis on the extent of the possible association
between phytoestrogens (including consumption and serum concentration) and the risk of PCa.
Methods: Eligible studies were retrieved via both computer searches and review of references. The summary
relative risk ratio (RR) or odds ratio (OR) and 95 % confidence interval (CI) were calculated with random effects
models.
Results: A total of 11 studies (2 cohort and 9 case–control studies) on phytoestrogen intake and 8 studies on
serum concentration were included in the meta-analysis. The pooled odds ratio (OR) showed a significant influence
of the highest phytoestrogens consumption (OR 0.80, 95 % CI 0.70–0.91) and serum concentration (OR 0.83, 95 % CI
0.70–0.99) on the risk of PCa. In stratified analysis, high genistein and daidzein intake and increased serum
concentration of enterolactone were associated with a significant reduced risk of PCa. However, no significant
associations were observed for isoflavone intake, lignans intake, or serum concentrations of genistein, daidzein,
or equol.
Conclusions: The overall current literature suggests that phytoestrogen intake is associated with a decreased risk of
PCa, especially genistein and daidzein intake. Increased serum concentration of enterolactone was also associated with
a significant reduced risk of PCa. Further efforts should be made to clarify the underlying biological mechanisms.
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Prostate cancer (PCa) was the second most frequently
diagnosed cancer and the sixth leading cause of death
from cancer among men worldwide in 2008 according
to the estimate of the International Agency for Research
on Cancer [1]. The worldwide PCa burden is expected
to grow to 1.7 million new cases and 499,000 new deaths
by 2030 simply due to the growth and aging of the glo-
bal population [2]. Given the 25-fold variation in disease
incidence between population at the highest and lowest
risk [1], lifestyle, diet, environmental, and genetic factors
have been suggested to play a role in the etiology of the
disease [3, 4]. The association between dietary factors* Correspondence: zjuwangs@gmail.com
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the low incidence of the cancer in Asia might be high
consumption of soybeans and its products [5, 6], which
are rich in one class of phytoestrogens known as
isoflavones.
Phytoestrogens, which have structural and functional
similarities to 17b-oestradiol, are believed to have a
prophylactic effect on PCa [7]. There are 3 main classes
of phytoestrogens: isoflavones, lignans, and coumestans.
In Western populations with a low intake of isoflavones,
phytoestrogen intake is predominantly derived from
intake of plant lignans. It is reported that isoflavones,
lignans, and their metabolites have anticarcinogenic
properties [8, 9]. Isoflavones principally include genis-
tein, daidzein, and glycitein. Equol is a metabolite of
daidzein produced by the intestinal microflora [10] that has
higher oestrogenic activity than its parent isoflavone. The
most abundant lignan in human subjects is enterolactone,distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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from plant lignan glycosides. Variation in individual
metabolism of phytoestrogens due to differences in gut
microflora [11] may influence the serum concentration of
phytoestrogens and their biologic effects. It is reported
that the capacity to produce equol has been found be to
lower among American than Japanese and Korean men
[12]. So, it is important to quantify the association
between serum concentration of phytoestrogens and
risk of PCa.
According to 2 previous meta-analyses [13, 14], con-
sumption of soy products rich in isoflavones are in-
versely associated with PCa risk. However, both of them
focused on the soy consumption neglecting the intake of
plant lignans (which is the primary phytoestrogen intake
in Western populations). Meanwhile, neither one eva-
luated the association between serum concentration of
phytoestrogens and risk of PCa.
Therefore, we performed a meta-analysis to address
this gap. We updated and assessed quantitatively the
association between intake of isoflavones and lignans
and risk of PCa from the cohort and case–control stud-
ies. We also investigated the association between serum
concentration of phytoestrogens and their metabolites
and the risk of PCa.
Methods
Search strategy
We identified relevant publications in the MEDLINE data-
base using PubMed, Web of Science, and the Cochrane
Library up to June 2014. Search terms included “phytoes-
trogens,” “isoflavones,” “lignans,” “flavonoids,” “genistein”
or “daidzein,” “glycitein,” “equol,” “enterolactone,” and
“enterodiol,” combined with “prostate cancer” or “pros-
tatic carcinoma”. Two of the authors (SW and JH)
reviewed the titles and abstracts independently to exclude
any clearly irrelevant studies. The full texts of the
remaining articles were read to determine whether they
contained information on the topic of interest. Any
disagreements were resolved by discussion. Furthermore,
references in the retrieved publications, as well as those in
previous reviews [15, 16], were checked for any other
pertinent studies.
Study selection
To be included, studies had to fulfill all of the following
inclusion criteria: (i) case–control or cohort study pub-
lished as an original article reported in English between
1980 and February 2014, (ii) estimated the relationship
between phytoestrogens (intake or serum concentration)
and the risk of PCa, (iii) provided a risk estimate relative
risk (RR) [or odds ratio (OR)] and its 95 % confidence
intervals (CI) or sufficient information allowing us to
compute them, and (iv) adjustment made for age andpotential risk factors. In studies with overlapping pa-
tients or controls, only the latest or the most informative
were included. Any study with inconsistent or erroneous
data was excluded. Meeting abstracts with insufficient
data or unpublished reports were not considered. We
included all methods for measuring exposure to phytoes-
trogens such as questionnaires, interviews, and serum
level or urinary excretion. We did not include studies that
used tumor-related biomarkers (such as PSA) as outcome.
We also exclude data concerning phytoestrogens and the
risk of recurrent PCa.
Data extraction
For each study, the following characteristics were ex-
tracted: last name of first author, publication year, country
in which the study was conducted, study design, popu-
lation type and sample size, adjustment for potential
confounders, definition of phytoestrogens exposure status,
and estimates of associations. The levels of phytoestrogens
exposure varied considerably among the studies, so we
extracted the most adjusted risk estimate of the highest
reported category of phytoestrogens exposure relative to
the lowest from these studies for comparison.
Statistical analyses
The ORs were used as the common measure of asso-
ciation across studies by considering the RRs as ORs.
The data from individual studies were pooled by use of
the random effects model with the DerSimonian-Laird
method [17], which considers within-study and between-
study variation. We performed subgroup analyses based
on different kinds of phytoestrogens. Certain items, such
as biochanin A, coumestrol, secoisolariciresinol, or
matairesinol, were seldom assessed in individual reports;
these analyses were not performed. Meta-regression ana-
lysis was used to assess the heterogeneity in publication
year, study conducted area, study design, and sample
size. The Q-statistic and I2 score were used to assess the
between-study heterogeneity of results [18, 19]. Publica-
tion bias assessment was done using the Egger regres-
sion asymmetry test [20] and the Begg-adjusted rank
correlation test [21]. If publication bias was observed,
the “trim and fill” method [22] was used to calculate an
estimate of the effect size after considering publication
bias (adjusted effect size). Possible outliers were visually
identified and tested for their effect on the significance
of the effect size. The statistical software used was Stata/
SE 11.0 (Stata Corporation, College Station, TX), and
the significance level was set to P < 0.05.
Results
Phytoestrogen intake
The detailed steps of our literature search are shown in
Fig. 1. We identified 13 studies that had investigated the
Fig. 1 Study selection process
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PCa risk. We excluded two studies [23, 24] from the
analysis because they were updated by Hedelin et al. [25]
and Word et al. [26]. The remaining 11 studies selected
for analysis are presented in Table 1. Two were cohort
studies [27, 28], and the other nine were case–control
studies. All of them used quantitative food frequency
questionnaire (FFQ) to measure phytoestrogen intake.
Two of these studies were quintile comparisons [27, 29],
six were quartile comparisons [25, 28, 30–33], and three
reported comparison between populations with low and
high intakes [26, 34, 35]. Of the studies, four were con-
ducted in North America, four in Europe, and three in
Asia. Because different kinds of phytoestrogens were
evaluated in these studies, some of which assessed more
than one kind of phytoestrogen, we chose the risk esti-
mate for the phytoestrogen kind that was representative
of their phytoestrogen intake in overall analysis. These
phytoestrogen kinds were prioritized in descending
order of total phytoestrogens or isoflavones, genistein,
daidzein, and lignans. Subsequently, we did the stratified
analysis of individual types of phytoestrogens.
We found that phytoestrogen intake (OR 0.80, 95 %
CI 0.70–0.91) was statistically significantly associated
with reduced risk of PCa with significant heterogeneity
(I2 = 47.7, P = 0.039). We used meta-regression analysis
to explore the influence of publication year, study design,
sample size, and study conducted area. However, none
was identified as a possible source of heterogeneity
among all the included studies (data not shown). Further
scrutiny found that the heterogeneity was reduced when
the analysis was stratified by geographical region (see
Fig. 2). The association was stronger among Asian (OR
0.62, 95 % CI 0.46–0.82) than American (OR 0.74, 95 %CI 0.56–0.98) and European (OR 0.90, 95 % CI 0.76–
1.06). The funnel plot showed some asymmetry. Begg’s
test (P = 0.043) and Egger’s test (P = 0.021) for publica-
tion bias were significant. The trim and fill analysis
yielded the same conclusions without evidence of any
potentially missed unpublished studies.
In stratified analysis of individual types of phytoestro-
gens (see Fig. 3), eight studies investigated the genistein
and daidzein, three studies tested lignans, and six studies
tested the isoflavones. The risk of PCa decreased signifi-
cantly in association with high consumption of genistein
(OR 0.83, 95 % CI 0.72–0.95) and daidzein (OR 0.82,
95 % CI 0.70–0.97), but high consumption of lignans
(OR 0.87, 95 % CI 0.69–1.09) and isoflavones (OR 0.93,
95 % CI 0.84–1.04) were not significantly associated with
the risk of PCa. Heterogeneity was detected (P = 0.035)
among the eight studies evaluating daidzein intake and
the risk of PCa. In contrast, there was no evidence of
heterogeneity among studies of genistein, lignans, and
isoflavones.
The Begg’s tests and Egger’s test provided no evidence
of publication bias for daidzein and isoflavones (data not
shown). However, for genistein analysis, the Begg’s tests
indicated no substantial publication bias (P = 0.083),
while the Egger’s test provided evidence for publication
bias (P = 0.005). We used the trim and fill method to es-
timate the missing studies. The result yielded the same
conclusions without evidence of any potentially missed
unpublished studies.
Serum phytoestrogens
We identified 10 studies that had investigated the associ-
ation between serum phytoestrogen concentration and
the risk for PCa. We excluded two studies [26, 36] be-
cause they presented results identical to those of a later
publication. One study [37] contained data from three
countries that were recently updated for two of these
countries [38, 39]. So, we included all these three studies
and extracted the latest data. The remaining 8 studies
selected for analysis are presented in Table 2. All of
them are case–control studies. Five of these studies are
quartile comparisons [25, 32, 37–39], two are tertile
comparison [40, 41], and one is a quintile comparison
[42]. Four studies investigated genistein, daidzein, and
equol [32, 40–42]. Six studies investigated the plasma
enterolactone [25, 32, 37–39, 42]. Only one study pro-
vided the relationship between serum isoflavones and
PCa risk [32]. In overall combination of serum phytoes-
trogens, these serum phytoestrogen kinds were priori-
tized in descending order of total isoflavones, genistein,
daidzein, equol, and enterolactone. The summary OR
was 0.83 (95 % CI 0.70–0.99), and the P value for het-
erogeneity was 0.525. The Begg funnel plots were sym-
metric, and the Egger’s tests provided no evidence of
Table 1 Epidemiologic studies on phytoestrogen intake in association with prostate cancer risk
Reference Study site/race Design Cases/controls or
cohort size
Dietary assessment Phytoestrogens Contrast Adjusted OR (95 % CI) Adjustment
Park et al.
[27] 2008
USA/multiethnic Cohort 4404/82,483 QFFQ (118 items) Genistein <0.7 vs. ≥3.1 mg/1000 kcal 0.94 (0.84–1.04) Time since cohort entry, ethnicity,
family history of prostate cancer,
education level, BMI, smoking status,
and energy intake
Daidzein <0.7 vs. ≥3.2 mg/1000 kcal 0.92 (0.82–1.02)
Total isoflavones <1.6 vs. ≥7.2 mg/1000 kcal 0.93 (0.83–1.04)
Kurahashi et al.
[28] 2007
Japan/Japanese Cohort 307/43,509 FFQ (147 items) Genistein <13.2 vs. ≥32.8 mg/day 0.71 (0.48–1.03) Age, area, smoking status, drinking
frequency, marital status, BMI, intake
of total fatty acids, dairy, vegetables,
and fruits
Daidzein <8.5 vs. ≥20.4 mg/day 0.77 (0.52–1.13)
Nagata et al.
[31] 2007
Japan/Japanese HCC 200/200 Semi-quantitative
FFQ
Isoflavones <30.5 vs. ≥89.9 mg/day 0.48 (0.25–0.93) Smoking, energy, and PUFA intake
Genistein <1.1 mg/day vs. ≥ 2.5
mg/day
0.68 (0.39–1.20)





Scotland/Scottish PCC 433/483 SCG-FFQ Isoflavones ≤581.1 μg/day vs.
≥1982.8 μg/day
1.18 (0.79–1.75) Age, total energy intake, family history
of PCa and BrCa, Carstairs Deprivation




Italy/Italian, HCC 1294/1451 FFQ Isoflavones ≤14.7 vs. ≥32.2 μg/day 0.98 (0.76–1.26) Terms for age, study center, education,
body mass index, family history of
prostate cancer, and total calorie intake
Hedelin et al.
[25] 2006
Sweden/Swedish PCC 1499/1130 FFQ (261 items) Phytoestrogens ≤1.18 vs. >4.71 μg/day 0.74 (0.57–0.95) Age, intake of antibiotics, zinc, animal
fat, total energy intake, alcohol,
vegetable fat, red meat during the
last year
Lignans ≤113 vs. >213 μg/day 0.85 (0.65–1.12)
Isoflavonoids ≤1.0 vs. >2.6 μg/day 0.99 (0.77–1.28)
Genistein ≤0.27 vs. >1.08 μg/d 0.97 (0.75–1.26)
Daidzein ≤0.49 vs. >1.11 μg/d 1.22 (0.92–1.62)
Lee et al.
[30] 2003
China/Chinese HCC 133/265 FFQ Genistein <17.9 vs. >62.0 mg/day 0.53 (0.29–0.97) Age and total calories





HCC 83/107 FFQ (modified block) Genistein Low vs. high 0.71 (0.39–1.30) Age, family history of prostate cancer,




USA/American PCC 433/538 FFQ (172 items) Lignans <335.4 vs. >603.9 μg/day 0.66 (0.47–0.94) Age, education, body mass index,








203/800 FFQ and 7-day
food diaries
Daidzein Low vs. high 0.88 (0.72–1.09) Age, height, weight, physical activity,
social class, family history of prostate
cancer, and daily intake of energy, fat,
zinc, selenium, dairy products,
and lycopene
Genistein 0.89 (0.72–1.09)
Total isoflavones 0.87 (0.70–1.09)














Table 1 Epidemiologic studies on phytoestrogen intake in association with prostate cancer risk (Continued)
Lewis et al.
[35] 2009
USA/American HCC 478/382 Block FFQ
(100 items)
Genistein ≤196.0 vs. >196.0 mcg 0.54 (0.33–0.89) Age, education, BMI, smoking history,
family history of prostate cancer in
first-degree relatives, and total
caloric intake
Daidzein ≤77.0 vs. >77.0 mcg 0.54 (0.33–0.89)
QFFQ quantitative food frequency questionnaire, PUFA polyunsaturated fatty acid, SCG-FFQ Scottish Collaborative Group-FFQ, EPIC European Prospective Investigation into Cancer and Nutrition, HCC hospital-based














Fig. 2 A forest plot showing pooled data for the association between phytoestrogen intake and prostate cancer risk in a variety of geographical
region
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conducted of individual types of serum phytoestrogens,
only serum enterolactone was inversely associated with
the risk of PCa with no heterogeneity (P = 0.183) (see
Fig. 4). High serum concentration of genistein, daidzein,
and equol were not associated with the risk of PCa (see
Fig. 4). There was no heterogeneity among these sub-
group studies. No publication bias was detected either
by Begg’s test or by Egger’s test in all subgroups (data
not shown).
Discussion
This meta-analysis demonstrated that consumption of
phytoestrogens was associated with a reduction in PCa
risk of 20 % in men when the highest reported intake
was compared with the lowest reported intake. The results
of our separate analysis based on the type of phytoestro-
gens showed inverse associations for the consumption of
genistein and daidzein and with increased serum concen-
trations of enterolactone. However, no significant associa-
tions were observed for isoflavone intake, lignan intake, or
serum level of genistein, daidzein, and equol.
It has been suggested that phytoestrogens may prevent
cancer by a variety of mechanisms, including sex and/
or growth hormone regulation, antioxidant properties,
apoptosis of PCa cells, and/or inhibition of angiogenesis,
invasion, and metastasis [43, 44]. These bioavailablemetabolites can be estimated from dietary intake data
by using in vitro data from incubation of foods with
human feces [45, 46], but this assessment does not
take into account interindividual variations in micro-
bial synthesis. Moreover, the quantification of the
phytoestrogen content of food can vary threefold to
fourfold, depending on variety, environmental factors,
growth, harvesting time, and processing [47]. So, the
associations between phytoestrogen intake and risk of
PCa were not so convincing. Measurement of metabolites
in blood and urine is considered to be more objective and
precise [48]. As we all know, human gut microflora have
been shown to exert metabolic activities on phytoestro-
gens [49]. As the gut microflora may differ by its concen-
tration and composition from one person to the other,
antimicrobials (i.e., antibiotics) may lead to intra- and
interindividual variations in amounts of intestinal phyto-
estrogen metabolites that are converted from consumed
phytoestrogens by the gut bacteria. In comparison to the
metabolism of isoflavones, biotransformation of lignans
has been found less variable [50]. This may explain why
we found a significant association with increased serum
concentrations of enterolactone but did not find signifi-
cant associations with serum concentrations of genistein,
daidzein, and equol. Of course, that may be also re-
lated to other bioactive isoflavone metabolites that were
not researched yet.
Fig. 3 A forest plot showing the pooled risk estimates of prostate cancer for different types of phytoestrogen intake
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domized controlled trials [51–56] that used phytoestro-
gens in man already diagnosed with PCa. Most of them
had small sample sizes and were of short duration.
These studies assessed the effect of soy/isoflavones on
tumor marker (prostate-specific antigen, PSA) or hor-
monal markers levels in men with PCa. So far, no study
was reported on 5-year survival or metastasis. A search
of ClinicalTrials.gov reveals numerous currently ongoing
trials that are investigating the role of phytoestrogens in
the treatment of PCa (i.e., NCT01126879, NCT01325311,
NCT01682941, NCT01036321, NCT00345813). The re-
sults of those studies will provide more evidence for the
role of phytoestrogens.
It is worth noting that in our analysis, stratification by
region yielded a significant inverse association with PCa
risk for studies in Asian populations, a marginally sig-
nificant inverse association with risk for studies in US
populations but no significant association with risk for
those in Europe populations. This difference may, in
part, be due to differences in environment and dietarypatterns in these regions. Characterization of the indi-
vidual variability as defined by the gut microflora com-
position and gene polymorphisms [23] may also help to
explain the discrepancies observed so far.
As a meta-analysis of previously published observa-
tional studies, our study has several limitations that need
to be taken into account. First, only English language
articles were included. We did not attempt to uncover
unpublished observations and did not include studies
with insufficient information to estimate an adjusted
OR, which could bring publication bias, even though the
trim and fill analysis yielded the same conclusions with-
out evidence of any potentially missed unpublished stud-
ies. Second, for now, the two available cohort studies
could not provide sufficient data for meta-analysis, so
we have to choose case–control studies as the data re-
source for analysis. In addition, because some items were
combined only from three studies, the total numbers of
cases remained low. Third, the intake levels of phytoestro-
gens in the lowest and highest categories and the range of
consumption level varied across studies. Moreover, food
Table 2 Epidemiologic studies on serum phytoestrogens concentrations in association with prostate cancer risk
Reference Study site/race Design Cases/controls Serum phytoestrogens Contrast Adjusted OR (95 % CI) Adjustment
Heald et al. [25] 2007 Scotland/Scottish PCC 249/205 Equol 0 vs. ≥0.10 nmol/l 1.07 (0.71–1.61) Age, total energy intake, family history of
PCa and BrCa, Carstairs Deprivation Index,
smoking and energy intake: BMR ratio.Daidzein ≤8.26 vs. >29.11 nmol/l 1.34 (0.76–2.38)
Genistein ≤14.23 vs. >64.53 nmol/l 1.36 (0.76–2.43)
Enterolactone ≤8.41 vs. >28.90 nmol/l 0.40 (0.22–0.71)
Hedelin et al. [32] 2006 Sweden/Swedish PCC 1499/1130 Enterolactone ≤15.2 vs. >37.8 nmol/l 0.74 (0.41–1.32) Age, intake of antibiotics, zinc, animal fat, total
energy intake, alcohol, vegetable fat, red meat
during the last year
Kurahashi et al. [40] 2007 Japan/Japanese NCC 307/43,509 Genistein <57 vs. ≥151.7 ng/ml 0.66 (0.40–1.08) Smoking status, alcohol intake, marital status,
and intake of green tea, protein, fiber, and
green or yellow vegetables.Daidzein <22 vs. ≥61.5 ng/ml 0.78 (0.49–1.25)
Equol <1.0 vs. ≥15.0 ng/ml 0.60 (0.36–0.99)
Ozasa et al. [41] 2004 Japan/Japanese NCC 52/151 Genistein <239 vs. >682 nM 0.76 (0.32–1.82) Age
Daidzein <89 vs. >239 nM 0.74 (0.31–1.76)
Equol <1.9 vs. >56.1 nM 0.39 (0.15–0.98)
Travis et al. [42] 2009 EPIC NCC 950/1042 Genistein <0.30 vs. ≥7.00 ng/ml 0.74 (0.54–1.00) Smoking, education, BMI, physical activity,
alcohol intake, and marital status
Daidzein <0.30 vs. ≥4.10 ng/ml 0.80 (0.60–1.07)
Equol <0.05 vs. ≥0.80 ng/ml 0.99 (0.70–1.39)
Enterolactone <0.05 vs. ≥0.80 ng/ml 0.77 (0.57–1.04)
Kilkkinen et al. [38] 2003 Finland NCC 214/214 Enterolactone <5.9 vs. ≥24.4 nmol/l 0.71 (0.42–1.21) Age match
Stattin et al. [37] 2002 Norway, Finland,
Sweden
NCC 794/2550 Enterolactone <8.9 vs. ≥27.89 nmol/l Finland 1.21 (0.91–1.60) Age match
<3.49 vs. ≥11.58 nmol/l Norway 1.02 (0.59–1.76)
<7.15 vs. ≥25.14 nmol/l Sweden 0.87 (0.45–1.67)
Stattin et al. [39] 2004 Sweden NCC 265/525 Enterolactone <9.38 vs. ≥28.31 nmol/l 1.05 (0.65–1.69) Age, BMI, smoking, and fasting















Fig. 4 A forest plot depicting the pooled risk estimates on the association between serum phytoestrogen concentration and prostate cancer risk
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lead to measurement errors. It is not only due to recall
bias but also to the estimation by using different food
composition databases, which may not be complete for
the whole range of foods consumed. On the other hand,
variation in individual metabolism of phytoestrogens due
to differences in gut microflora and measurement in a sin-
gle blood or urine sample may only reflect recent dietary
intake. These differences may have contributed to the het-
erogeneity among studies. To be honest, phytoestrogen
spectrum and content varies between the plant species,
sort, and origin. Even the same molecule arising from the
different sources can exert various effects. It may not be
excluded that synthetic phytoestrogens with desirable
structure and activity could be an easier and safer alterna-
tive of the traditional plant product of variable origin,
phytoestrogen content, and activity. Several studies are go-
ing on developing novel and more selective synthetic
phytoestrogens.
Conclusions
Our findings support the hypotheses that serum entero-
lactone and consumption of genistein and daidzein pro-
tect against PCa risk. Interestingly enough, an associationbetween PCa risk and isoflavone intake or serum concen-
trations of its metabolites was not found. The complexity
of phytoestrogen composition and its metabolism make
the evaluation of the effect of phytoestrogen on PCa very
difficult. In the light of these findings, further prospective
epidemiological studies using improved food databases
and experimental studies are needed to identify the spe-
cific compounds that provide protection, to determine
precisely how the complex metabolism of phytoestrogens
may interact with other mechanisms to prevent cancer.
Synthetic phytoestrogens with desirable structure and
activity could be an easier and safer alternative of the trad-
itional plant product.
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